Publications by authors named "Thomas Dejgaard"

Claim this Profile
E
Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real-world evidence.
Alexandra A Weinreich, Jonatan I Bagger, Jeanette T Jørgensen, Peter L Kristensen, Thomas F Dejgaard

Diabetes Obes Metab· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trial.
David S Mathiesen, Josefine V Hansen, Aske Høck, Casper K Nielsen, Miriam G Pedersen, Thomas F Dejgaard

Diabetes Obes Metab· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose-dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes-A randomised placebo-controlled study.
Bjørn Hoe, Sebastian M N Heimbürger, Lærke S Gasbjerg, Amalie R Lanng, Mads B Lynggaard, Thomas F Dejgaard

Diabetes Obes Metab· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study.
Elisabeth B Stougaard, Mads R Andersen, Jonatan I Bagger, Esben Søndergaard, Jakob A Østergaard, Thomas F Dejgaard

Diabetes Obes Metab· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Transition From Multiple Daily Injection Therapy to Automated Insulin Delivery in People With Type 1 Diabetes and Limited Diabetes Self-Management.
Mette J Nitschke, Maria H Hemmingsen, Hanne H Nørgaard, Kristina A Robak, Pia Nørrevang, Thomas F Dejgaard

J Diabetes Sci Technol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.
Thomas F Dejgaard, Christian S Frandsen, Urd Kielgast, Joachim Størling, Anne J Overgaard

Diabetes Obes Metab· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes.
Sebastian Møller Nguyen Heimbürger, Bjørn Hoe, Chris Neumann Nielsen, Natasha Chidekel Bergman, Kirsa Skov-Jeppesen, Thomas Fremming Dejgaard

J Clin Endocrinol Metab· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endurance Training Improves GLP-1 Sensitivity and Glucose Tolerance in Overweight Women.
Thorbjörn Åkerström, Malene N Stolpe, Renate Widmer, Thomas F Dejgaard, Jens M Højberg

J Endocr Soc· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.
Signe Schmidt, Christian S Frandsen, Thomas F Dejgaard, Dorte Vistisen, Thórhallur Halldórsson

Diabetes Obes Metab· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.
Nicklas J Johansen, Thomas F Dejgaard, Asger Lund, Camilla Schlüntz, Bolette Hartmann

Diabetes Obes Metab· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
Thomas F Dejgaard, Bernt J von Scholten, Erik Christiansen, Frederik F Kreiner, Lars Bardtrum

Diabetes Obes Metab· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial.
Sebastian M N Heimbürger, Bjørn Hoe, Chris N Nielsen, Natasha C Bergmann, Bolette Hartmann, Thomas F Dejgaard

Diabetologia· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Letter to the Editor from McKee and McGill: "Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring".
Caroline T B Juel, Thomas F Dejgaard, Carsten P Hansen, Jan H Storkholm, Tina Vilsbøll

J Clin Endocrinol Metab· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring.
Caroline T B Juel, Thomas F Dejgaard, Carsten P Hansen, Jan H Storkholm, Tina Vilsbøll

J Clin Endocrinol Metab· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial.
Kristine Færch, Martin B Blond, Lea Bruhn, Hanan Amadid, Dorte Vistisen, Thomas F Dejgaard

Diabetologia· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.
Nicklas J Johansen, Thomas F Dejgaard, Asger Lund, Camilla Schlüntz, Emil L Larsen

Diabetes Obes Metab· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
Thomas F Dejgaard, Signe Schmidt, Christian S Frandsen, Dorte Vistisen, Sten Madsbad

Diabetes Obes Metab· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
Nicklas J Johansen, Thomas F Dejgaard, Asger Lund, Camilla Schlüntz, Christian S Frandsen

Lancet Diabetes Endocrinol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.
Sebastian M Heimbürger, Andreas Brønden, Nicklas J Johansen, Thomas F Dejgaard, Tina Vilsbøll

Expert Opin Pharmacother· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes.
Christian Stevns Hansen, Christian Seerup Frandsen, Jesper Fleischer, Dorte Vistisen, Jens Juul Holst, Thomas Fremming Dejgaard

Front Endocrinol (Lausanne)· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration and complications of diabetes mellitus and the associated risk of infective endocarditis.
Lauge Østergaard, Ulrik M Mogensen, Johan S Bundgaard, Anders Dahl, Andrew Wang, Thomas Fremming Dejgaard

Int J Cardiol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
Nicklas Järvelä Johansen, Thomas Fremming Dejgaard, Asger Lund, Tina Vilsbøll, Henrik Ullits Andersen

BMJ Open· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-insulin pharmacological therapies for treating type 1 diabetes.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad, Jens Juul Holst

Expert Opin Pharmacother· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy.
Jesper Fleischer, Esben Laugesen, Simon Lebech Cichosz, Pernille Hoeyem, Thomas Fremming Dejgaard

J Diabetes Complications· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
Lauge Østergaard, Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad

Expert Rev Clin Pharmacol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis